Clinicopathological characteristics at primary melanoma diagnosis as risk factors for brain metastasis

Melanoma Research

Volumn 23, Issue 6, 2013, Pages 461-467

  Qian, Meng ^a   Ma, Michelle W ^a,b   Fleming, Nathaniel H ^a,b   Lackaye, Daniel J ^a,b   Hernando, Eva ^a,b   Osman, Iman ^a,b,c   Shao, Yongzhao ^a,b,c  

^a NEW YORK UNIVERSITY SCHOOL OF MEDICINE   (United States)

^b Interdisciplinary Melanoma Cooperative Group   (United States)

^c NEW YORK UNIVERSITY   (United States)

Author keywords

brain neoplasms; competing risk; melanoma; neoplasm metastasis

Indexed keywords

ADVANCED CANCER; ARTICLE; BRAIN METASTASIS; CANCER DIAGNOSIS; CANCER RISK; CANCER STAGING; CANCER SURVIVAL; CONTROLLED STUDY; CUTANEOUS MELANOMA; DATA BASE; FEMALE; FOLLOW UP; HUMAN; MAJOR CLINICAL STUDY; MALE; ONCOLOGICAL PARAMETERS; PRIMARY MELANOMA; PRIMARY TUMOR; PRIORITY JOURNAL; PROPORTIONAL HAZARDS MODEL; SURVIVAL TIME; TUMOR ULCERATION; TUMOR VOLUME;

ADOLESCENT; ADULT; AGED; AGED, 80 AND OVER; BRAIN NEOPLASMS; CHILD; CHILD, PRESCHOOL; COHORT STUDIES; DISEASE-FREE SURVIVAL; FEMALE; HUMANS; MALE; MELANOMA; MIDDLE AGED; MULTIVARIATE ANALYSIS; PROPORTIONAL HAZARDS MODELS; RISK FACTORS; SKIN NEOPLASMS; TREATMENT OUTCOME; YOUNG ADULT;

EID: 84887586235     PISSN: 09608931     EISSN: 14735636     Source Type: Journal    
DOI: 10.1097/CMR.0000000000000015     Document Type: Article

References (22)

1. Nayak L, Lee EQ, Wen PY. Epidemiology of brain metastases. Curr Oncol Rep 2012; 14:48-54
2. Kohler BA, Ward E, McCarthy BJ, Schymura MJ, Ries LA, Eheman C, et al. Annual report to the nation on the status of cancer, 1975-2007, featuring tumors of the brain and other nervous system. J Natl Cancer Inst 2011; 103:714-736
3. Chamberlain MC. Brain metastases: a medical neuro-oncology perspective. Expert Rev Neurother 2010; 10:563-573
4. Byrne TN, Cascino TL, Posner JB. Brain metastasis from melanoma. J Neurooncol 1983; 1:313-317
5. Bindal RK, Sawaya R, Leavens ME, Lee JJ. Surgical treatment of multiple brain metastases. J Neurosurg 1993; 79:210-216
6. Eigentler TK, Figl A, Krex D, Mohr P, Mauch C, Rass K, et al. Number of metastases, serum lactate dehydrogenase level, and type of treatment are prognostic factors in patients with brain metastases of malignant melanoma. Cancer 2011; 117:1697-1703
7. Sampson JH, Carter JH Jr, Friedman AH, Seigler HF. Demographics, prognosis, and therapy in 702 patients with brain metastases from malignant melanoma. J Neurosurg 1998; 88:11-20
8. Zakrzewski J, Geraghty LN, Rose AE, Christos PJ, Mazumdar M, Polsky D, et al. Clinical variables and primary tumor characteristics predictive of the development of melanoma brain metastases and post-brain metastases survival. Cancer 2011; 117:1711-1720
9. Cohn-Cedermark G, Mansson-Brahme E, Rutqvist LE, Larsson O, Johansson H, Ringborg U. Central nervous system metastases of cutaneous malignant melanoma - a population-based study. Acta Oncol 1998; 37:463-470
10. Daryanani D, Plukker JT, de Jong MA, Haaxma-Reiche H, Nap R, Kuiper H, et al. Increased incidence of brain metastases in cutaneous head and neck melanoma. Melanoma Res 2005; 15:119-124
11. Bedikian AY, Wei C, Detry M, Kim KB, Papadopoulos NE, Hwu WJ, et al. Predictive factors for the development of brain metastasis in advanced unresectable metastatic melanoma. Am J Clin Oncol 2011; 34:603-610
12. Kopf AW, Gross DF, Rogers GS, Rigel DS, Hellman LJ, Levenstein M, et al. Prognostic index for malignant melanoma. Cancer 1987; 59: 1236-1241
13. Wich LG, Hamilton HK, Shapiro RL, Pavlick A, Berman RS, Polsky D, et al. Developing a multidisciplinary prospective melanoma biospecimen repository to advance translational research. Am J Transl Res 2009; 1:35-43
14. Balch CM, Gershenwald JE, Soong SJ, Thompson JF, Atkins MB, Byrd DR, et al. Final version of 2009 AJCC melanoma staging and classification. J Clin Oncol 2009; 27:6199-6206
15. Friedman EB, Shang S, Miera EV, Fog JU, Teilum MW, Ma MW, et al. Serum microRNAs as biomarkers for recurrence in melanoma. J Transl Med 2012; 10:155
16. Satzger I, Mattern A, Kuettler U, Weinspach D, Voelker B, Kapp A, et al. MicroRNA-15b represents an independent prognostic parameter and is correlated with tumor cell proliferation and apoptosis in malignant melanoma. Int J Cancer 2010; 126:2553-2562
17. Gray RJ. A class of K-sample tests for comparing the cumulative incidence of a competing risk. Ann Stat 1988; 16:1141-1154
18. Fine JP, Gray RJ. A proportional hazards model for the subdistribution of a competing risk. J Am Stat Assoc 1999; 94:496-509
19. Saltman BE, Ganly I, Patel SG, Coit DG, Brady MS, Wong RJ, et al. Prognostic implication of sentinel lymph node biopsy in cutaneous head and neck melanoma. Head Neck 2010; 32:1686-1692
20. Eggermont AM, Spatz A, Lazar V, Robert C. Is ulceration in cutaneous melanoma just a prognostic and predictive factor or is ulcerated melanoma a distinct biologic entity? Curr Opin Oncol 2012; 24:137-140
21. Zettersten E, Sagebiel RW, Miller JR 3rd, Tallapureddy S, Leong SP, Kashani-Sabet M. Prognostic factors in patients with thick cutaneous melanoma ( 4 mm). Cancer 2002; 94:1049-1056
22. Long GV, Trefzer U, Davies MA, Kefford RF, Ascierto PA, Chapman PB, et al. Dabrafenib in patients with Val600Glu or Val600Lys BRAF-mutant melanoma metastatic to the brain (BREAK-MB): a multicentre, open-label, phase 2 trial. Lancet Oncol 2012; 13:1087-1095.